What we are studying
The purpose of this research study is to determine the additional benefit (standard therapy is also given) of glucocorticoids (“steroids”) injected directly into the arteries that supply the parts of your gastrointestinal tract affected by acute GvHD.
Since standard therapy produces satisfactory resolution in less than half the cases, new options must be considered. One such option is the injection of the most proven agents, glucocorticoids (specifically methylprednisone [Solu-Medrol]), directly into the arteries that supply the gastrointestinal tract. This method has been helpful in some patients with GvHD that did not respond to primary therapy with glucocorticoids and might work better when used in addition to standard therapy earlier in the course of GvHD.
Parking validation will be provided for study-related visits